Colorectal Cancer (CRC) Active Not Recruiting Phase 1 Trials for Irinotecan (DB00762)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Active Not Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03368963	TAS102 in Combination With NAL-IRI in Advanced GI Cancers	Treatment	Irinotecan (DB00762) Tipiracil (DB09343) Trifluridine (DB00432)
NCT03337087	Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer	Treatment	Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Levoleucovorin (DB11596) Rucaparib (DB12332)
NCT06838338	JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Glecirasib (DB18744) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT06607185	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors	Treatment	Carboplatin (DB00958) Cetuximab (DB00002) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) LY4066434 (DB22727) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037) Pemetrexed (DB00642)
NCT05846867	A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer	Treatment	AK119 (DB16423) Fluorouracil (DB00544) Irinotecan (DB00762) Ivonescimab (DB18931) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT05722327	Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer	Treatment	Adagrasib (DB15568) Cetuximab (DB00002) Irinotecan (DB00762)
NCT05277766	Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer	Treatment	Irinotecan (DB00762)
NCT03872947	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors	Treatment	Bevacizumab (DB00112) Carboplatin (DB00958) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Imiquimod (DB00724) Irinotecan (DB00762) Leucovorin (DB00650) Nivolumab (DB09035) Paclitaxel (DB01229) Pegylated doxorubicin (DB32018) Pembrolizumab (DB09037) Ramucirumab (DB05578) TRK-950 (DB22441)
NCT03795311	Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526)
NCT06011772	EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer	Treatment	Bevacizumab (DB00112) Cetuximab (DB00002) Fluorouracil (DB00544) Incomplete Freund's adjuvant (DB17475) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Panitumumab (DB01269) Recombinant human EGF-rP64K (DB25065)
NCT05838768	Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.	Treatment	HRO761 (DB24029) Irinotecan (DB00762) Pembrolizumab (DB09037)